Why the US Government Wants to End the Biden Pill Penalty in Medicare?

=Biden Pill Penalty: A part of President Joe Biden’s Inflation Reduction Act is causing strong reactions in the medical world. Many drug developers and health experts are upset, saying the rule is hurting progress in creating easy-to-take medicines like pills. Some have started calling the rule the “Biden Pill Penalty” because of how it impacts small-molecule drug research.

The problem comes from a rule that lets the government set prices on certain drugs only nine years after they are approved. This rule affects pills and other small-molecule drugs but not the more expensive biologics, which get a 13-year window before price control begins.

Critics say this change has led to a 70% drop in investment in new pills since 2021. They believe the rule is pushing companies to stop working on affordable pill-based treatments and move toward costly options like injections and IV drugs.

Top 10 Best Hospitals in the US: Highest Rated by Medicare and Medicaid Patients

Joel White, who leads the Council for Affordable Health Coverage, explained why this is a problem. “The Biden IRA has been a nightmare for American patients and is causing sky-rocketing out-of-pocket costs on Pill Penalty prescriptions,” he said in a comment to the Washington Reporter. White added, “Joe Biden and Democrats in Congress have forced the drug companies to move away from developing the kinds of drugs patients prefer – because they’re easier to take, more affordable, and more widely available.”

Biden Pill Penalty: Fewer Pills, Higher Costs, Bigger Problems

Because of this rule, experts are warning that fewer pill-based medicines may come out in the future. Instead, drug companies are putting more money into biologics. Reports say biologics now receive ten times more investment than pills. A study from the University of Chicago predicts that this shift could mean 79 new drugs won’t be developed. It also warned that this could cut a total of 116 million years off people’s lives in the U.S. over the next two decades.

This change may also lead to serious problems for people with long-term diseases like heart disease, diabetes, and cancer. Pills are often easier for these patients to use, and they usually cost less.

Who Qualifies for Medicaid in 2025? Updated Poverty Guidelines Released

But with fewer pills being made, these patients might end up paying more and have fewer treatment options. Experts also fear that this will put more pressure on hospitals and clinics and make it harder for people to stay healthy and continue working.

The policy was meant to lower drug prices, but many now say it is backfiring. Critics argue that it’s leading to fewer choices, higher costs, and harm to the country’s role in medicine. As the debate continues, the future of pill-based treatment in the U.S. looks uncertain.